Below are the most recent publications written about "Post-Exposure Prophylaxis" by people in Profiles.
-
Barn?s-Valldejuly O, Wurzl A, Church B. Clinical Risk Assessment and Treatment of a Man Attacked by a Rabid North American Beaver (Castor canadensis) in the Connecticut River: Case Report. Wilderness Environ Med. 2025 Jun; 36(2):263-266.
-
Anderson JC, Boakye MDS, Draughon Moret J. Patient and Provider Decision Making About HIV Postexposure Prophylaxis Following Sexual Violence: A Qualitative Analysis. J Assoc Nurses AIDS Care. 2023 Nov-Dec 01; 34(6):566-581.
-
Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton JH, Gerber J, Levine AC, Naeim A, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, Fukuta Y, Gawad AL, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park HS, Pekosz A, Petrini J, Rausch W, Shade DM, Shapiro JR, Singleton JR, Sutcliffe C, Thomas DL, Yarava A, Zand M, Zenilman JM, Tobian AAR, Sullivan DJ. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clin Infect Dis. 2023 02 08; 76(3):e477-e486.
-
Ejemel M, Smith TG, Greenberg L, Carson WC, Lowe D, Yang Y, Jackson FR, Morgan CN, Martin BE, Kling C, Hutson CL, Gallardo-Romero N, Ellison JA, Moore S, Buzby A, Sullivan-Bolyai J, Klempner M, Wang Y. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 06 07; 12(1):9403.
-
Wormser GP, Warshafsky S, Visintainer P. Aggregation of data from 4 clinical studies demonstrating efficacy of single-dose doxycycline postexposure for prevention of the spirochetal infections: Lyme disease, syphilis, and tick-borne relapsing fever. Diagn Microbiol Infect Dis. 2021 Apr; 99(4):115293.
-
Gogtay NJ, Munshi R, Ashwath Narayana DH, Mahendra BJ, Kshirsagar V, Gunale B, Moore S, Cheslock P, Thaker S, Deshpande S, Karande S, Kumbhar D, Ravish HS, Harish BR, Pisal SS, Dhere R, Parulekar V, Blackwelder WC, Molrine DC, Kulkarni PS. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study. Clin Infect Dis. 2018 01 18; 66(3):387-395.
-
Gogtay N, Thatte U, Kshirsagar N, Leav B, Molrine D, Cheslock P, Kapre SV, Kulkarni PS. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012 Nov 26; 30(50):7315-20.
-
Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett S, Levis R, Meltzer MI, Schaffner W, Cieslak PR. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine. 2009 Nov 27; 27(51):7141-8.